February 15, 2013 / 3:16 PM / 5 years ago

BRIEF-GlaxoSmithKline says Dolutegravir granted FDA priority review

LONDON, Feb 15 (Reuters) - GlaxoSmithKline Plc : * Dolutegravir granted FDA priority review * FDA has assigned Dolutegravir a prescription drug user fee act (PDUFA) target

date of 17 August 2013 * Viiv Healthcare announces FDA priority review designation for dolutegravir as

a potential treatment for hiv infection * Source text

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below